Everhart Financial Group Inc. Has $1.07 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Everhart Financial Group Inc. raised its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 33.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,209 shares of the pharmaceutical company's stock after buying an additional 553 shares during the period. Everhart Financial Group Inc.'s holdings in Vertex Pharmaceuticals were worth $1,071,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of VRTX. Mascagni Wealth Management Inc. acquired a new position in Vertex Pharmaceuticals in the fourth quarter worth about $31,000. Truvestments Capital LLC lifted its holdings in Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after buying an additional 23 shares during the last quarter. Mpwm Advisory Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $40,000. Midwest Capital Advisors LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $41,000. Finally, Minot DeBlois Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at approximately $44,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

VRTX has been the subject of several recent research reports. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. Bank of America lifted their price target on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a report on Monday, March 31st. Royal Bank of Canada increased their price objective on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Leerink Partnrs cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $515.04.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX traded down $4.61 during midday trading on Friday, reaching $455.45. The company's stock had a trading volume of 1,021,326 shares, compared to its average volume of 1,417,847. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a market cap of $116.96 billion, a price-to-earnings ratio of -207.02, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a 50 day moving average price of $462.88 and a 200 day moving average price of $460.24. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Vertex Pharmaceuticals's quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $4.76 EPS. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.